Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods

Journal of Molecular Modeling

Volumn 17, Issue 3, 2011, Pages 477-493

  Cheng, Jianxin ^a   Liu, Guixia ^a   Zhang, Jing ^a   Xu, Zhejun ^a   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Homology modeling; Molecular docking; Opioid receptor agonists; Opioid receptors; Pharmacophore; Receptor ligand interaction

Indexed keywords

ADRENERGIC RECEPTOR; ANALGESIC AGENT; DELTA OPIATE RECEPTOR AGONIST; HYDROGEN; KAPPA OPIATE RECEPTOR AGONIST; LIGAND; MU OPIATE RECEPTOR AGONIST;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR BINDING; SENSITIVITY AND SPECIFICITY;

ANALGESICS, OPIOID; BINDING SITES; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79954433689     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-010-0745-1     Document Type: Article

References (83)

1. AZ Zhang GW Pasternak 1981 Ontogeny of opioid pharmacology and receptors: high and low affinity site differences Eur J Pharmacol 73 29 40 10.1016/0014-2999(81)90142-4 1:CAS:528:DyaL3MXls1WltLc%3D (Pubitemid 11094396)
2. GW Pasternak 2001 Insights into mu opioid pharmacology the role of mu opioid receptor subtypes Life Sci 68 2213 2219 10.1016/S0024-3205(01)01008-6 1:CAS:528:DC%2BD3MXivVaru78%3D (Pubitemid 32454484)
3. TJ Martin JC Eisenach 2001 Pharmacology of opioid and nonopioid analgesics in chronic pain states J Pharmacol Exp Ther 299 811 817 1:CAS:528:DC%2BD3MXovVCksbs%3D (Pubitemid 33104946)
4. AM Trescot S Datta M Lee H Hansen 2008 Opioid pharmacology Pain Physician 11 S133 S153
5. Y Zhu MA King AG Schuller, et al. 1999 Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice Neuron 24 243 252 10.1016/S0896-6273(00)80836-3 1:CAS:528:DyaK1MXmsVOrs7g%3D (Pubitemid 29466162)
6. CM Cahill A Morinville C Hoffert D O'Donnell A Beaudet 2003 Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control Pain 101 199 208 10.1016/S0304-3959(02)00333-0 1:CAS:528:DC%2BD38XpvVait78%3D (Pubitemid 36044668)
7. L Bao SX Jin C Zhang, et al. 2003 Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion Neuron 37 121 133 10.1016/S0896-6273(02)01103-0 1:CAS:528:DC%2BD3sXmtFGmtg%3D%3D (Pubitemid 36106439)
8. DL DeHaven-Hudkins RE Dolle 2004 Peripherally restricted opioid agonists as novel analgesic agents Curr Pharm Des 10 743 757 10.2174/1381612043453036 1:CAS:528:DC%2BD2cXhvFOktbc%3D (Pubitemid 38292402)
9. U Holzgrabe W Brandt 2003 Mechanism of action of the diazabicyclononanone-type kappa-agonists J Med Chem 46 1383 1389 10.1021/jm0210360 1:CAS:528:DC%2BD3sXitVOls7c%3D (Pubitemid 36512702)
10. S Soukara CA Maier U Predoiu A Ehret R Jackisch B Wunsch 2001 Methylated analogues of methyl (R)-4-(3, 4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl) piperazine-1-carboxylate (GR-89, 696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies J Med Chem 44 2814 2826 10.1021/jm0108395 1:CAS:528:DC%2BD3MXltlSnt7k%3D (Pubitemid 32879722)
11. Johnson H (1978) Quantitative stereo-structure-activity relationships I. Opiate receptor binding. NIDA Res Monogr 146-158
12. SK Ray SC Basak C Raychaudhury AB Roy JJ Ghosh 1982 A quantitative structure-activity relationship study of N-alkylnorketobemidones and triazinones using structural information content Arzneimittelforschung 32 322 325 1:CAS:528:DyaL38Xltlyisbc%3D (Pubitemid 12147514)
13. BL Podlogar GI Poda DA Demeter, et al. 2000 Synthesis and evaluation of 4-(N, N-diarylamino)piperidines with high selectivity to the delta-opioid receptor: a combined 3D-QSAR and ligand docking study Drug Des Discov 17 34 50 1:CAS:528:DC%2BD3cXltlSmtL4%3D (Pubitemid 30410013)
14. XQ Huang HL Jiang XM Luo, et al. 2000 Molecular modeling on solvent effect and interaction mechanism of fentanyl analogs to mu-opioid receptor Acta Pharmacol Sin 21 46 54
15. Y Peng SM Keenan Q Zhang WJ Welsh 2005 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs J Mol Graph Model 24 25 33 10.1016/j.jmgm.2005.05.001 1:CAS:528:DC%2BD2MXhtVehs7%2FL (Pubitemid 41318115)
16. XH Wang Y Tang Q Xie ZB Qiu 2006 QSAR study of 4-phenylpiperidine derivatives as mu opioid agonists by neural network method Eur J Med Chem 41 226 232 10.1016/j.ejmech.2005.10.017 1:CAS:528:DC%2BD28XislCit7o%3D
17. W Li Y Tang Q Xie W Sheng ZB Qiu 2006 3D-QSAR studies of orvinol analogs as kappa-opioid agonists J Mol Model 12 877 884 10.1007/s00894-005-0084-9 1:CAS:528:DC%2BD28XhtFOitL7E (Pubitemid 44480318)
18. E Greiner M Spetea R Krassnig, et al. 2003 Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14- phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships J Med Chem 46 1758 1763 10.1021/jm021118o 1:CAS:528:DC%2BD3sXisVaktLY%3D (Pubitemid 36444228)
19. JR Carson SJ Coats EE Codd, et al. 2004 N, N-dialkyl-4-[(8-azabicyclo[3. 2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists Bioorg Med Chem Lett 14 2109 2112 10.1016/j.bmcl.2004.02.051 1:CAS:528:DC%2BD2cXjtVehtb8%3D (Pubitemid 38481371)
20. V Kumar MA Marella L Cortes-Burgos, et al. 2000 Arylacetamides as peripherally restricted kappa opioid receptor agonists Bioorg Med Chem Lett 10 2567 2570 10.1016/S0960-894X(00)00519-9 1:CAS:528:DC%2BD3cXosVCqsbY%3D
21. HJ Breslin C Cai TA Miskowski, et al. 2006 Identification of potent phenyl imidazoles as opioid receptor agonists Bioorg Med Chem Lett 16 2505 2508 10.1016/j.bmcl.2006.01.082 1:CAS:528:DC%2BD28XislCgs7s%3D
22. GH Chu M Gu JA Cassel, et al. 2006 Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists Bioorg Med Chem Lett 16 645 648 10.1016/j.bmcl.2005.10.034 1:CAS:528:DC%2BD2MXhtlCiu7nE (Pubitemid 43014851)
23. JM Macdougall XD Zhang WE Polgar TV Khroyan L Toll JR Cashman 2004 Synthesis and biological evaluation of some 6-arylamidomorphines as analogues of morphine-6-glucuronide Bioorg Med Chem 12 5983 5990 10.1016/j.bmc.2004.08.019 1:CAS:528:DC%2BD2cXovFWrsLs%3D (Pubitemid 39388197)
24. HJ Breslin TA Miskowski BM Rafferty, et al. 2004 Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders J Med Chem 47 5009 5020 10.1021/jm030548r 1:CAS:528:DC%2BD2cXnt1GmtL0%3D (Pubitemid 39314899)
25. M Anzini L Canullo C Braile, et al. 2003 Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1, 4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity J Med Chem 46 3853 3864 10.1021/jm0307640 1:CAS:528:DC%2BD3sXmtVCntLc%3D (Pubitemid 37038094)
26. AD Jordan MJ Orsini SA Middleton, et al. 2005 8-(Heteroaryl)phenalkyl-1- phenyl-1, 3, 8-triazaspiro[4.5]decan-4-ones as opioid receptor modulators Med Chem 1 601 610 10.2174/157340605774598207 1:CAS:528:DC%2BD2MXhtFyht7rK
27. SJ Coats MJ Schulz JR Carson, et al. 2004 Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct- 3-ylidene)-aryl-methyl]-benzam ides, powerful mu and delta opioid agonists Bioorg Med Chem Lett 14 5493 5498 10.1016/j.bmcl.2004.09.004 1:CAS:528:DC%2BD2cXos1eju78%3D (Pubitemid 39346332)
28. V Kumar D Guo JA Cassel, et al. 2005 Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists Bioorg Med Chem Lett 15 1091 1095 10.1016/j.bmcl.2004.12.018 1:CAS:528:DC%2BD2MXos1Cmtg%3D%3D (Pubitemid 40458654)
29. C Dardonville C Fernandez-Fernandez SL Gibbons, et al. 2006 Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites Bioorg Med Chem 14 6570 6580 10.1016/j.bmc.2006.06.007 1:CAS:528:DC%2BD28XosVOitbs%3D (Pubitemid 44233317)
30. O Azzolina S Collina L Linati, et al. 2001 Enantiomers of 2-[(Acylamino)ethyl]-1, 4-benzodiazepines, potent ligands of kappa-opioid receptor: chiral chromatographic resolution, configurational assignment and biological activity Chirality 13 606 612 10.1002/chir.1185 1:CAS:528: DC%2BD3MXnslCqt7g%3D (Pubitemid 32958517)
31. AC Hiebel YS Lee E Bilsky, et al. 2007 Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series J Med Chem 50 3765 3776 10.1021/jm061325e 1:CAS:528:DC%2BD2sXnsVymsLk%3D (Pubitemid 47292040)
32. AA Trabanco N Aerts RM Alvarez, et al. 2007 4-Phenyl-4-[1H-imidazol-2-yl] -piperidine derivatives as non-peptidic selective delta-opioid agonists with potential anxiolytic/antidepressant properties. Part 2 Bioorg Med Chem Lett 17 3860 3863 10.1016/j.bmcl.2007.05.012 1:CAS:528:DC%2BD2sXmvVCltb0%3D (Pubitemid 46920955)
33. R Lattanzi M Spetea F Schullner, et al. 2005 Synthesis and biological evaluation of 14-alkoxymorphinans. 22. (1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities J Med Chem 48 3372 3378 10.1021/jm040894o 1:CAS:528: DC%2BD2MXjtVOjt7o%3D (Pubitemid 40637205)
34. J Schutz M Spetea M Koch, et al. 2003 Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: an extremely powerful analgesic J Med Chem 46 4182 4187 10.1021/jm030878b (Pubitemid 37122460)
35. GH Chu M Gu JA Cassel, et al. 2005 Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2, 3-dihydrobenzofuran-based constraints Bioorg Med Chem Lett 15 5114 5119 10.1016/j.bmcl.2005.08.094 1:CAS:528:DC%2BD2MXhtFCntrjL (Pubitemid 41463630)
36. C Dardonville N Jagerovic LF Callado JJ Meana 2004 Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites Bioorg Med Chem Lett 14 491 493 10.1016/j.bmcl.2003.10.048 1:CAS:528:DC%2BD3sXhtVSiu7fK (Pubitemid 38045152)
37. A Coop RB Rothman C Dersch, et al. 1999 delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole J Med Chem 42 1673 1679 10.1021/jm9807003 1:CAS:528: DyaK1MXitlCmtLo%3D (Pubitemid 29226737)
38. C Beguin MR Richards Y Wang, et al. 2005 Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2) Bioorg Med Chem Lett 15 2761 2765 10.1016/j.bmcl.2005.03.113 1:CAS:528: DC%2BD2MXks1Wjtbs%3D (Pubitemid 40732215)
39. D Page N Nguyen S Bernard, et al. 2003 New scaffolds in the development of mu opioid-receptor ligands Bioorg Med Chem Lett 13 1585 1589 10.1016/S0960-894X(03)00194-X 1:CAS:528:DC%2BD3sXivFelsLc%3D (Pubitemid 36428566)
40. IJ Kim T Ullrich JW Janetka, et al. 2003 Diaryldimethylpiperazine ligands with mu- and delta-opioid receptor affinity: Synthesis of (+)-4-[(alphaR)- alpha-(4-allyl-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyp henyl)methyl]-N- ethyl-N-phenylbenzamide and (-)-4-[(alphaR)-alpha-(2S, 5S)-dimethylpiperazin-1- yl)-(3-hydroxyphenyl)met hyl]-N-ethyl-N-phenylbenzamide Bioorg Med Chem 11 4761 4768 10.1016/S0968-0896(03)00496-6 1:CAS:528:DC%2BD3sXnvVymu7w%3D (Pubitemid 37230132)
41. GH Chu M Gu JA Cassel, et al. 2007 Novel malonamide derivatives as potent kappa opioid receptor agonists Bioorg Med Chem Lett 17 1951 1955 10.1016/j.bmcl.2007.01.053 1:CAS:528:DC%2BD2sXis1Onsr8%3D (Pubitemid 46367664)
42. G Loriga I Manca G Murineddu, et al. 2006 Synthesis of 3, 6-diazabicyclo[3.1.1]heptanes as novel ligands for the opioid receptors Bioorg Med Chem 14 676 691 10.1016/j.bmc.2005.09.045 1:CAS:528:DC%2BD2MXhtlSiurnP (Pubitemid 41767572)
43. AA Trabanco S Pullan JM Alonso, et al. 2006 4-Phenyl-4-[1H-imidazol-2-yl] -piperidine derivatives, a novel class of selective delta-opioid agonists Bioorg Med Chem Lett 16 146 149 10.1016/j.bmcl.2005.09.025 1:CAS:528: DC%2BD2MXht1Citr7K (Pubitemid 41625661)
44. GA Pinna G Cignarella G Loriga, et al. 2002 N-3(9)-arylpropenyl-N-9(3)- propionyl-3, 9-diazabicyclo[3.3.1]nonanes as mu-opioid receptor agonists. Effects on mu-affinity of arylalkenyl chain modifications Bioorg Med Chem 10 1929 1937 10.1016/S0968-0896(01)00436-9 1:CAS:528:DC%2BD38XisFWhur8%3D (Pubitemid 34286385)
45. P Grundt IA Williams JW Lewis SM Husbands 2004 Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1, 1-dimethyl-7-hydroxytetralin pharmacophore J Med Chem 47 5069 5075 10.1021/jm040807s 1:CAS:528:DC%2BD2cXnt12gtrY%3D (Pubitemid 39314904)
46. GD Ho A Bercovici D Tulshian, et al. 2007 Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1 Bioorg Med Chem Lett 17 3023 3027 10.1016/j.bmcl.2007. 03.061 1:CAS:528:DC%2BD2sXlt1Kjtbc%3D (Pubitemid 46702637)
47. JP Caldwell JJ Matasi H Zhang A Fawzi DB Tulshian 2007 Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands Bioorg Med Chem Lett 17 2281 2284 10.1016/j.bmcl.2007.01.069 1:CAS:528:DC%2BD2sXjvVaitrk%3D (Pubitemid 46484307)
48. MP Wentland X Sun Y Ye R Lou JM Bidlack 2003 Redefining the structure-activity relationships of 2, 6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues Bioorg Med Chem Lett 13 1911 1914 10.1016/S0960-894X(03)00295-6 1:CAS:528:DC%2BD3sXjs1ersLk%3D (Pubitemid 36577140)
49. MP Wentland Y Ye CL Cioffi, et al. 2003 Syntheses and opioid receptor binding affinities of 8-amino-2, 6-methano-3-benzazocines J Med Chem 46 838 849 10.1021/jm020429w 1:CAS:528:DC%2BD3sXovFyrtw%3D%3D (Pubitemid 36258874)
50. GD Ho A Bercovici D Tulshian, et al. 2007 Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2 Bioorg Med Chem Lett 17 3028 3033 10.1016/j.bmcl.2007. 03.062 1:CAS:528:DC%2BD2sXlt1Kjur4%3D (Pubitemid 46702638)
51. K Palczewski T Kumasaka T Hori, et al. 2000 Crystal structure of rhodopsin: A G protein-coupled receptor Science 289 739 745 10.1126/science.289. 5480.739 1:CAS:528:DC%2BD3cXlslOqs78%3D (Pubitemid 30650186)
52. HR Bourne EC Meng 2000 Structure. Rhodopsin sees the light Science 289 733 734 10.1126/science.289.5480.733 1:CAS:528:DC%2BD3cXlslOru7w%3D (Pubitemid 30650182)
53. H Luecke B Schobert JK Lanyi EN Spudich JL Spudich 2001 Crystal structure of sensory rhodopsin II at 2.4 angstroms: insights into color tuning and transducer interaction Science 293 1499 1503 10.1126/science.1062977 1:CAS:528:DC%2BD3MXmsVeqsLw%3D (Pubitemid 32801553)
54. M Iadanza M Holtje G Ronsisvalle HD Holtje 2002 Kappa-opioid receptor model in a phospholipid bilayer: molecular dynamics simulation J Med Chem 45 4838 4846 10.1021/jm0209127 1:CAS:528:DC%2BD38XntlOrtLo%3D (Pubitemid 35192773)
55. CB Fowler ID Pogozheva H LeVine 3rd HI Mosberg 2004 Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites Biochemistry 43 8700 8710 10.1021/bi036067r 1:CAS:528:DC%2BD2cXkvVGgt7c%3D (Pubitemid 38880040)
56. M Aburi PE Smith 2004 Modeling and simulation of the human delta opioid receptor Protein Sci 13 1997 2008 10.1110/ps.04720304 1:CAS:528: DC%2BD2cXmtlCrsr0%3D (Pubitemid 38989607)
57. Y Zhang YY Sham R Rajamani J Gao PS Portoghese 2005 Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system Chembiochem 6 853 859 10.1002/cbic.200400207 1:CAS:528: DC%2BD2MXksFajsb8%3D (Pubitemid 40873746)
58. W Li Y Tang YL Zheng ZB Qiu 2006 Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists Bioorg Med Chem 14 601 610 10.1016/j.bmc.2005.08.052 1:CAS:528:DC%2BD2MXhtlSiurjJ (Pubitemid 41767564)
59. V Cherezov DM Rosenbaum MA Hanson, et al. 2007 High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 318 1258 1265 10.1126/science.1150577 1:CAS:528:DC%2BD2sXhtlGmur7I (Pubitemid 350172884)
60. DM Rosenbaum V Cherezov MA Hanson, et al. 2007 GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function Science 318 1266 1273 10.1126/science.1150609 1:CAS:528:DC%2BD2sXhtlGmur7J (Pubitemid 350172885)
61. J Greene S Kahn H Savoj P Sprague S Teig 1994 Chemical function queries for 3D database search J Chem Inf Comput Sci 16 1297 1308
62. BR Brooks RE Broccoleri BD Olafson DJ States S Swaminathan M Karplus 1983 CHARMM: a program for macromolecular energy J Comput Chem 4 187 217 10.1002/jcc.540040211 1:CAS:528:DyaL3sXit1aiu7w%3D
63. JM Rollinger S Haupt H Stuppner T Langer 2004 Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example J Chem Inf Comput Sci 44 480 488 1:CAS:528: DC%2BD2cXkvVWkuw%3D%3D
64. CATALYST, 4.10. Accelrys Inc. http://www.accelrys.com : San Diego, CA
65. PP Roy K Roy 2008 On some aspects of variable selection for partial least squares regression models QSAR Comb Sci 27 302 313 10.1002/qsar.200710043 1:CAS:528:DC%2BD1cXlt1Kqsbg%3D
66. A Sali TL Blundell 1993 Comparative protein modelling by satisfaction of spatial restraints J Mol Biol 234 779 815 10.1006/jmbi.1993.1626 1:CAS:528:DyaK2cXnt1ylug%3D%3D (Pubitemid 24007801)
67. A Sali JP Overington 1994 Derivation of rules for comparative protein modeling from a database of protein structure alignments Protein Sci 3 1582 1596 10.1002/pro.5560030923 1:CAS:528:DyaK2cXmsFSmu7g%3D (Pubitemid 24314476)
68. G Chang WC Still WC Guida 1989 An internal coordinate Monte Carlo method for searching conformational space J Am Chem Soc 111 4379 4386 10.1021/ja00194a035 1:CAS:528:DyaL1MXitlSrsLo%3D
69. F Mohamadi NGJ Richards WC Guida, et al. 1990 Macromodels-An integrated software system for modeling organic and bioorganic molecules using molecular mechanics J Comput Chem 11 440 467 10.1002/jcc.540110405 1:CAS:528: DyaK3cXktl2msLw%3D
70. Glide, 5.0, 2008. Schrödinger, LLC
71. Prime, 2.0, 2008. Schrödinger, LLC
72. J Zhang K Yu W Zhu H Jiang 2006 Neuraminidase pharmacophore model derived from diverse classes of inhibitors Bioorg Med Chem Lett 16 3009 3014 10.1016/j.bmcl.2006.02.054 1:CAS:528:DC%2BD28XjvFygtLY%3D
73. EE Codd RP Shank JJ Schupsky RB Raffa 1995 Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception J Pharmacol Exp Ther 274 1263 1270 1:CAS:528:DyaK2MXot1yjsb4%3D
74. DL DeHaven-Hudkins LC Burgos JA Cassel, et al. 1999 Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity J Pharmacol Exp Ther 289 494 502 1:CAS:528:DyaK1MXit1Khur4%3D (Pubitemid 29156067)
75. M Filizola HO Villar GH Loew 2001 Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties J Comput Aided Mol Des 15 297 307 10.1023/A:1011187320095 1:CAS:528:DC%2BD3MXjsFeqtLg%3D (Pubitemid 32366721)
76. N Singh G Cheve DM Ferguson CR McCurdy 2006 A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist J Comput Aided Mol Des 20 471 493 10.1007/s10822-006-9067-x 1:CAS:528:DC%2BD28Xht1erurnF (Pubitemid 44823885)
77. CK Surratt PS Johnson A Moriwaki, et al. 1994 mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity J Biol Chem 269 20548 20553 1:CAS:528:DyaK2cXlsV2htbs%3D
78. K Fukuda S Kato K Mori 1995 Location of regions of the opioid receptor involved in selective agonist binding J Biol Chem 270 6702 6709 10.1074/jbc.270.12.6702 1:CAS:528:DyaK2MXks1yisLg%3D
79. T Sagara H Egashira M Okamura I Fujii Y Shimohigashi K Kanematsu 1996 Ligand recognition in mu opioid receptor: experimentally based modeling of mu opioid receptor binding sites and their testing by ligand docking Bioorg Med Chem 4 2151 2166 10.1016/S0968-0896(96)00219-2 1:CAS:528:DyaK2sXhtVyktrk%3D (Pubitemid 27060227)
80. ID Pogozheva AL Lomize HI Mosberg 1998 Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints Biophys J 75 612 634 10.1016/S0006-3495(98)77552-6 1:CAS:528:DyaK1cXltFyitr4%3D (Pubitemid 28357504)
81. G Subramanian MG Paterlini DL Larson PS Portoghese DM Ferguson 1998 Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists J Med Chem 41 4777 4789 10.1021/jm9803166 1:CAS:528:DyaK1cXmvVKjtbw%3D (Pubitemid 28530454)
82. A Lavecchia G Greco E Novellino F Vittorio G Ronsisvalle 2000 Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations J Med Chem 43 2124 2134 10.1021/jm991161k 1:CAS:528:DC%2BD3cXjtFKhtLY%3D (Pubitemid 30354537)
83. Thirstrup K, Hjorth SA, Schwartz TW (1996) In Investigation of the Binding Pocket in the Kappa Opioid Receptor by a Combination of Alanine Substitutions and Steric Hindrance Mutagenesis. 27th Meeting of the International Narcotics Research Conference, Poster M30